Immediate Impact
52 standout
Citing Papers
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
2024 Standout
Works of Marco Sborgia being referenced
Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
2008
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
2005
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Marco Sborgia | 45 | 45 | 29 | 35 | 7 | 124 | |
| Keith Sibson | 47 | 43 | 27 | 30 | 11 | 144 | |
| N. Peter | 23 | 80 | 53 | 40 | 8 | 166 | |
| O. Legrand | 59 | 132 | 50 | 10 | 7 | 206 | |
| Charlotte Wood | 32 | 46 | 99 | 8 | 7 | 207 | |
| Juliana Silva | 14 | 47 | 17 | 22 | 6 | 140 | |
| José Sánchez de Toledo Codina | 29 | 13 | 38 | 18 | 10 | 112 | |
| Jennie B. Feliu | 106 | 134 | 89 | 21 | 6 | 215 | |
| Betty Prine | 33 | 39 | 38 | 40 | 6 | 109 | |
| Joshua Hessler | 37 | 14 | 4 | 13 | 7 | 138 | |
| Kevin Jestice | 22 | 84 | 11 | 12 | 8 | 172 |
All Works
Loading papers...